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Background/Aims: Intestinal metaplasia (IM) has been re-
garded as a premalignant condition. This study evaluated the 
role of the transforming factor CDX2 according to the severity 
and type of IM. Methods: This analysis was performed on 
383 subjects with IM in the antrum and/or body, with diag-
noses that were categorized as controls, dysplasias, and gas-
tric cancers. The IM grades were classiﬁ  ed into four groups 
as negative, mild, moderate or severe using the updated 
Sydney scoring system. The IM subtypes were categorized as 
type I, type II, and type III using high iron diamine and alcian 
blue (pH 2.5) staining. The CDX2 expression in the IM foci 
was evaluated using immunohistochemistry in specimens 
from the antrum and/or body. Results: CDX2 expression 
increased according to IM severity (p=0.001) but was not as-
sociated with the IM subtype (p=0.881) in the antrum speci-
mens. Similarly, CDX2 expression increased according to the 
IM grade (p=0.001) but was not associated with the IM sub-
type (p=0.755) in the body specimens. CDX2 expression was 
also increased according to baseline disease in the antrum, 
especially dysplastic and GC group (p=0.003), but not in the 
body (p=0.582). However, status of Helicobacter pylori infec-
tion was not associated with CDX2 expression in the antrum 
(p=0.692) and body (p=0.271). Conclusions: These results 
show that CDX2 expression is associated with the IM grade 
regardless of the IM subtype and that it was more frequent in 
the dysplasia group. These results suggest that CDX2 expres-
sion might play an important role in the progression of IM in 
various environments that can affect neoplastic change. (Gut 
Liver 2012;6:71-77)
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INTRODUCTION
Gastric cancer (GC) is one of the most common malignancies 
in Korea. The risk factors for GC are known to be Helicobacter 
pylori infection, atrophic gastritis (AG), and intestinal metapla-
sia (IM). IM is defined as the replacement of gastric columnar 
epithelial cells by cells with intestinal morphology, which ap-
pears in the multi-step progression of GC, especially in the 
intestinal type GC as proposed by Correa.
1 According to Correa 
hypothesis, H. pylori was thought to play a crucial role in the 
formation and progression of IM. That was generally accepted 
in the epidemiologic and population-based study,
2,3 though 
arguing data were existed.
4 In addition, there was not com-
mon consensus about the effect of H. pylori on the subtype or 
progression of IM in these epidemiologic studies. Furthermore, 
IM was considered to be irreversible change in spite of H. pylori 
eradication.
5 Therefore, the beneficial effect of H. pylori eradica-
tion was not clear in the area of already formed IM.
In regard to the property of IM itself, it is important to search 
the high risk of IM in the gastric carcinogenesis and frequent 
surveillance may be needed in this IM. Many investigations 
have researched the molecular and genetic mechanisms of IM, 
and have attempted to classify IM according to the risk for 
developing GC. Jass and Filipe
6 suggested a classification of 
IM based on morphology and classic mucin staining, and the 
incomplete type (type II and III) was considered to have a higher 
risk for GC than the complete type (type I).
7,8 Another classifica-
tion of IM was suggested according to the gastric phenotype as 
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and-intestinal (GI) mixed type, and intestinal (I) type.
9 Many 
arguments still existed in the classification of IM for the cancer 
risk in spite of these efforts.
10 Furthermore, the extensive IM was 
thought to be more important as a gastric carcinogenesis than 
subtype.
11
CDX2, a member of the caudal-related homeobox gene family 
and intestinal-specific transcriptional factor, plays an important 
role in the development of small and large intestine.
12 Aberrant 
expression of CDX2 was observed in the gastric IM and vari-
ous site of adenocarcinoma.
13,14 The crucial role of CDX2 in the 
formation of IM has been identified in the transgenic mice and 
gastric carcinoma was observed in the CDX2 transgenic mice.
15 
In our previous study, CDX1 and CDX2 were found to play an 
important role in the formation of IM and in the progression to 
dysplasia and GC in human gastric specimens using real-time 
polymerase chain reaction (RT-PCR) method.
16 However, this is 
only gene level that it is necessary to be proved by protein level. 
Nevertheless, there have not been well-known about the roles of 
CDX2 transcriptional factor in the subtype or progression of IM 
until now. In addition, there were few data regarding the role of 
CDX2 in the progression of gastric carcinogenesis related with 
H. pylori infection by the immunohistochemistry (IHC) method. 
From this background, we tried to investigate the role of the 
CDX2 transcriptional factor in the formation and progression of 
IM among the diverse gastric disorders such as gastritis, dyspla-
sia, and GC using IHC method. 
MATERIALS AND METHODS
1. Study subjects
Three hundred and eighty-three patients were enrolled from 
2003 to 2007 in Seoul National University Bundang Hospital. 
Approximately 50% of the patients had gastrointestinal symp-
toms within 3 months, but most of them received gastroscopy 
for the GC screening. The subjects were categorized into three 
groups, mainly depending on the gastroscopy findings and his-
tological diagnosis; a control group and two different disease 
groups (dysplasia and GC). As CDX2 expression usually appears 
in the presence of IM, the study pool for IHC of CDX2 was se-
lected when there was microscopic IM finding in either antrum 
or body after H&E staining. In GC group, poorly differentiated 
or signet ring cell type GC was excluded because these types 
of GC are usually thought to be not associated with multistep 
progression of GC. Subjects with a history of gastric surgery, H. 
pylori eradication therapy or systemic diseases requiring chronic 
medication were excluded. The Institutional Review Board at 
Seoul National University Bundang Hospital approved this 
study, and written informed consent was obtained from all of 
the participants. 
2. H. pylori testing and histology
To determine the presence of current H. pylori infection, 10 
biopsy specimens were obtained for the three types of H. pylori 
testing (histology, Campylobacter like organism [CLO] test [Delta 
West, Bentley, Australia], and culture). Among them, two biopsy 
specimens (one each from the greater curvature and lesser cur-
vature) of the antrum and body were fixed in formalin, respec-
tively, and used for evaluation of the presence of gastric atrophy 
(loss of appropriate glands including both metaplastic and non-
metaplstic atrophy) and IM (by H&E staining). The presence of 
atrophy on any of two specimens in the antrum and body were 
averaged regarding gastric atrophy, and the same method was 
applied to IM. For determination of H. pylori, modified Giemsa 
staining was performed for two specimens from each of the an-
trum and body, and histological features of gastric mucosa were 
recorded using the updated Sydney scoring system. All biopsies 
were examined independently by two experienced patholo-
gists (H.S.L. and Hee Eun Lee), who were unaware of the patient 
details. In the event of disagreement, the biopsies were reex-
amined by these two pathologists until agreement was reached. 
One specimen from each of the lesser curvature of the antrum 
and body was used for CLO test. Two specimens from each of 
the antrum and body were used for culture. If any one of these 
three H. pylori tests were positive, then the host was regarded 
as having an ongoing H. pylori infection. The anti-H. pylori im-
munoglobulin G (Genedia H. pylori ELISA; Green Cross Medical 
Science Co., Eumsung, Korea) was also determined when the 
three above-mentioned H. pylori tests were negative.
17 Korean 
strain was used as antigen in this H. pylori antibody test. When 
the H. pylori serology was positive, these subjects were regarded 
as having past H. pylori infection and classified as H. pylori-
positive.
3. HID-AB2.5 staining for metaplasia subtyping
Sulfated (brown) and acidic non-sulfated (blue) mucosub-
stances were simultaneously stained with high iron diamine 
and alcian blue (pH 2.5) (HID-AB2.5). The IM was classified as 
follows: type I, mature absorptive cells and goblet cells, the lat-
ter secreting sialomucins; type II, few or absent absorptive cells, 
presence of columnar ‘intermediate’ cells in various stages of 
differentiation secreting sialomucins or, occasionally, sulfomu-
cins, or both; type III, columnar intermediate cells secreting pre-
dominantly sulfomucins and goblet cells secreting sialomucins 
or sulfomucins, or both.
18 If more than one HID subtype of IM 
was present, it was classified as the dominant IM phenotype. In 
addition, the pathologists (H.S.L. and H.E.L) were blinded to the 
clinical information of the patients.
4. IHC for CDX2
Tissues from the antrum and body were fixed in 10% neutral 
buffered formalin, paraffin-embedded, and then cut into sec-
tions (4 μm). IHC was performed by the standard avidin-biotin 
complex method. A monoclonal antibody for CDX2 (BioGenex; 
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antibody and anti-mouse immunoglobulin G (Sigma, St Louis, 
MO, USA) labeled with biotin was used as a secondary antibody. 
Negative controls were treated similarly with the exception of 
the primary antibodies. The whole areas of slides were evalu-
ated and positive CDX2 IHC was defined by at least more than 
10% staining of the IM foci (Fig. 1).
19 Among 383 subjects, the 
specimen of 42 in the antrum and that of 155 in the body were 
excluded from CDX2 staining due to no observable foci of IM, 
respectively. In addition, 49 and 24 subjects with IM foci could 
not be used in CDX2 IHC, mainly due to loss of paraffin block. 
Finally, the specimen of the antrum (293 subjects) and body (204 
subjects) were used in CDX2 IHC. 
5. Statistical analysis
All statistical analyses were performed using SPSS software 
version 15.0 (SPSS Inc., Chicago, IL, USA). The Pearson chi-
square test was used to compare pairs of groups and Student’s 
t-test was used to compare the mean value of each group. p-
value below 0.05 was considered as a statistically significant. 
RESULTS
1. Baseline characteristics
The 383 subjects with histological IM was classified to three 
groups: control group (n=165), dysplastic group (n=67), and GC 
group (n=151). The baseline characteristics are shown in Table 
1. The mean age and the proportion of male were higher in the 
dysplastic and GC group, respectively (p<0.001). The severity of 
AG was higher in dysplasia and GC group than control group in 
the body specimens (p<0.001), but has no significant difference 
in the antrum specimens (p=0.769) (Table 1).
2. Pathological features of IM
The distribution and pathologic features of IM that were de-
termined by an updated Sydney classification were shown in 
Table 2. One  antrum specimen was not obtained for histology 
in control group and one body specimen in GC group. There-
fore, 164 antrum specimens were used for the analysis of IM 
grade and extent in control group and 150 body specimens in 
GC group (Table 2). More extended distribution of IM was ob-
served in the dysplasia and GC groups than the control group 
Table 1. Baseline Characteristics 
Characteristic
Control 
(n=165)
Dysplasia 
(n=67)
Gastric 
cancer 
(n=151)
p-value
Age, yr 58.6±12.6 63.3±8.4 65.0±9.4 <0.001*
Sex <0.001
̈
Male 93 (56.4) 52 (78.8) 114 (75.5)
Female  72 (43.6) 15 (21.2)  37 (24.5)
H. pylori positivity 0.326
̈
H. pylori positive 146 (88.5) 63 (94.0) 128 (84.8)
H. pylori negative  19 (11.5)  4 (6.0)  23 (15.2)
Atrophic gastritis
Antrum 0.769
̈
None 34 (31.8) 11 (32.4) 32 (39.0)
Mild 46 (43.0) 10 (29.4) 25 (30.5)
Moderate 20 (18.7) 11 (32.4) 15 (18.3)
Severe 7 (6.5) 2 (5.9) 10 (12.2)
Body <0.001
̈
None 63 (64.3) 11 (28.9) 26 (32.1)
Mild 16 (16.3) 10 (26.3) 19 (23.5)
Moderate 18 (18.4) 13 (34.2) 29 (35.8)
Severe 1 (1.0)  4 (10.5) 7 (8.6)
Data are presented as mean±SD or number (%). Bold indicates statis-
tical significance.
*One-way ANOVA test; 
̈Chi-square test.
Fig. 1. Immunohistochemistry of CDX2. (A) Negative, (B) weak positive, and (C) strong positive (×200).74  Gut and Liver, Vol. 6, No. 1, January 2012
(p<0.001). That is, dysplasia and cancer group showed IM in 
both of antrum and body, 65.7% and 62.7%, respectively, but 
control group showed 31.1%. In addition, The IM grade deter-
mined by an updated Sydney classification was more severe in 
the dysplastic and GC groups than in the control group, in both 
antrum (p=0.001) and body (p<0.001). However, there was no 
significant difference when comparing according to the sub-
types of IM in both the antrum and body (Table 2). 
3. CDX2 IHC
The specimen of the antrum (293 subjects) and body (204 
subjects) were stained by CDX2 IHC. CDX2 expression was 
demonstrated in 219 (74.7%) and 169 (82.8%), respectively. 
CDX2 expression was increased with IM grade in the antrum 
(p=0.001) and body (p=0.001). However, CDX2 expression was 
not associated with IM subtype in the antrum and body (Table 3). 
In addition, CDX2 expression was higher in the dysplasia and 
GC group than control group in the antrum (p=0.003), but not 
in the body (p=0.582) (Table 3). 
4. H. pylori status
There was no significant difference between H. pylori-positive 
and -negative group in terms of IM grade, IM subtype, and 
CDX2 expression in both of antrum and body (Table 4). 
DISCUSSION
In this study, we demonstrated that CDX2 expression was as-
sociated with IM grade, but not subtype. These results suggest 
that CDX2 plays a role in the formation of IM. The biology of 
gastric IM has been investigated regarding variant molecular 
and genetic factors such as Shh, BMP4, CDX1, CDX2, and C-
myc et al., but the formation and progression of IM is still dif-
ficult and undisclosed area.
20 Among the efforts, the transgenic 
mice model has shown that CDX transcriptional factors play 
Table 2. The Relationship between Underlying Disease Groups and 
IM Extension, Grade, and Subtype
Variable Control Dysplasia
Gastric 
cancer
p-value*
Extension of IM <0.001
One side 113 (58.9) 23 (12.0) 56 (29.2)
Both side 51 (27.0) 44 (23.3) 94 (49.7)
Grade of IM
Antrum 0.001
None 23 (56.1) 8 (19.5) 10 (24.4)
Mild 75 (51.7) 20 (13.8) 50 (34.5)
Moderate 55 (38.2) 24 (16.7) 65 (46.9)
Severe 11 (21.2) 15 (28.8) 26 (50.0)
Body <0.001
None 90 (59.6) 15 (9.9) 46 (30.5)
Mild 41 (40.6) 21 (20.8) 39 (38.6)
Moderate 30 (31.3) 21 (21.9) 45 (46.9)
Severe 4 (11.8) 10 (29.4) 20 (58.8)
Subtype of IM
Antrum 0.427
Type I 18 (50.0) 4 (11.1) 14 (38.9)
Type II 45 (42.1) 20 (18.7) 42 (39.3)
Type III 39 (38.2) 13 (12.7) 50 (49.0)
Body 0.150
Type I 21 (39.6) 14 (26.4) 18 (34.0)
Type II 29 (28.7) 20 (19.8) 52 (51.5)
Type III 11 (37.9) 3 (10.3) 15 (51.7)
Data are presented as number (%). Bold indicates statistical signifi-
cance.
IM, intestinal metaplasia.
*Chi-square test.
Table 3. IM Grade, Subtype, and Disease Status according to CDX2 
Expression
Variable CDX2 negative CDX2 positive p-value*
Grade of IM
   Antrum 0.001
     Mild 43 (34.7) 81 (65.3)
     Moderate 26 (20.3) 102 (79.7)
     Severe 5 (12.2) 36 (87.8)
   Body 0.001
     Mild 26 (28.6) 65 (71.4)
     Moderate 8 (9.8) 74 (90.2)
     Severe 1 (3.2) 30 (96.8)
Subtype of IM
   Antrum 0.881
     Type I 9 (25.7) 26 (74.3)
     Type II 22 (22.9) 74 (77.1)
     Type III 23 (23.7) 74 (76.3)
   Body 0.755
     Type I 7 (13.7) 44 (86.3)
     Type II 9 (9.3) 88 (90.7)
     Type III 5 (18.5) 22 (81.5)
Disease group
  Antrum 0.003
     Control 39 (34.8) 73 (65.2)
     Dysplasia+GC 35 (19.3) 146 (80.7)
   Body 0.582
     Control 12 (19.4) 50 (80.6)
     Dysplasia+GC 23 (16.2) 119 (83.8)
Data are presented as number (%). Bold indicates statistical signifi-
cance.
IM, intestinal metaplasia; GC, gastric carcinoma.
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a crucial role in the formation of IM.
21 Furthermore, GC was 
developed in the CDX2 transgenic mice model.
15 In the present 
study, the CDX2 expression was found to be 74.7% and 82.8% 
in the antrum and body, which are quite similar to the previ-
ous data, about 80%.
22-24 IHC for CDX2 was performed for the 
positive IM specimen, our data suggest that IM could be present 
without CDX2 in human stomach, and the CDX transcriptional 
factors might not be the unique factors in the IM formation. 
That is, other factors such as bile reflux, genetic or environmen-
tal factor might intermediate IM formation, especially in case of 
CDX-2 negative subjects.
There has been a great diversity of opinions in the role of 
CDX2 in gastric carcinogenesis. Some reports even claimed that 
CDX2 transcriptional factor may act as a tumor suppressor.
25,26 
In the present study, CDX2 expression was increased in the neo-
plastic groups (dysplasia and GC) in the antrum, but not in the 
body, suggesting that CDX2 is not directly with gastric carci-
nogenesis. Instead, CDX2 looks like to be important in the pro-
gression of IM to the more severe and widespread form. There is 
a high chance of development of dysplasia and intestinal type 
of GC in this environment. In our previous study, we preformed 
quantitative analysis using RT-PCR for the evaluation of the 
role of CDX1 and CDX2 in the formation of IM and the progres-
sion to dysplasia and GC.
16 In this study which is not identical 
pool with the present study, CDX2 transcriptional factor was 
associated with both IM grade and subtype. Taken together, 
quantitative study such as RT-PCR might be a more powerful 
tool regarding the role of CDX2 in the research of IM biology. 
However, RT-PCR is based on transcriptional level but not on 
the translational level that IHC research could be very definite 
in supporting data. In the present study, CDX2 expression by 
IHC was correlated with IM grade, which is the identical finding 
of RT-PCR. Autoregulatory effect of CDX2 transcriptional factor 
has been assumed for this relationship. That is, CDX2 could au-
toregulate itself by binding CDX2 promotor area.
27 We also tried 
to perform the IHC of CDX1 but we could not find the adequate 
antibody for human study in spite of several times of trial. 
The direct relationship of CDX2 expression and H. pylori 
infection was not confirmed.
22,28-30 However, disappearance of 
CDX2 expression was observed by H. pylori eradication in the 
level of gastritis in the absence of definitive IM.
29,30 However, 
H. pylori eradication did not cause any effects on the CDX2 
expression when IM was already documented.
22,28 In addition, 
a recent study has shown that low degree of CDX2 expres-
sion was observed more than 50% in subjects with normal and 
healthy gastric mucosa without evidence of H. pylori infection, 
and bile reflux is one of the assumptive mechanisms in that 
case.
30,31 In the present study, the prevalence of H. pylori was 
not associated with IM grade, IM subtype and CDX2 expres-
sion. However, CDX2 expression was significantly higher in the 
H. pylori-positive group than -negative group when RT-PCR 
method was used in our previous study.
16 There could be several 
reasons. First, CDX2 IHC method may have limitation as the 
interpretation is not simple, which is different from quantitative 
study. Another reason could be study design. That is, the present 
study was not age and sex-matched study, which is different 
from the previous study. In addition, the prevalence of H. pylori 
in the control group of the present study was 88.5%, which was 
not different from dysplasia or GC group. This prevalence of H. 
pylori in the control group is much higher than 51.4% in com-
parison to the population-based study during similar periods.
32 
The main reason of high prevalence of H. pylori, 88.5% is selec-
tion criteria of the present study. That is, as CDX2 expression 
usually appears in the presence of IM the study pool for IHC of 
CDX2 was selected when there was microscopic IM finding in 
either antrum or body regardless of control, dysplasia, and GC 
in the present study. This result suggests that H. pylori plays an 
important role in the formation of IM.  
Incomplete type (type II and III) of IM was considered to be 
more important in the carcinogenesis than complete type (type I), 
but statistical significance was usually marginal.
7,8 Instead, a lot 
of studies demonstrated that the extension of IM was important 
risk for the gastric carcinogenesis.
11,33-35 In the present study, IM 
grade and extension were more important than IM subtype with 
GC progression in the background IM. This finding is consis-
tent with the results of prior studies demonstrating that the IM 
subtype was less important than the extension or grade of IM.
11 
There have been few data regarding the IM grade as a high risk 
Table 4. IM Grade, Subtype, and CDX2 Expression according to H. 
pylori Status
Variable 
H. pylori 
negative
H. pylori 
positive
p-
value*
Grade of IM
   Antrum 0.512
     None/Mild/Moderate/Severe 6/14/17/9 35/131/127/43
   Body 0.768
     None/Mild/Moderate/Severe 17/11/12/6 134/90/84/28
Subtype of IM
   Antrum 0.619
     Type I/II/III 6/15/11 30/92/91
   Body 0.505
     Type I/II/III 7/12/6 46/89/23
CDX2 expression
   Antrum 0.692
     Negative 9 (12.2) 65 (87.8)
     Positive 23 (10.5) 196 (89.5)
   Body 0.271
     Negative 6 (17.1) 29 (82.9)
     Positive 20 (11.8) 149 (88.2)
Data are presented as number (%). 
IM, intestinal metaplasia.
*Chi-square test. 76  Gut and Liver, Vol. 6, No. 1, January 2012
factor for the gastric carcinogenesis. However, the present study 
suggests that IM grade might be an important factor as IM ex-
tension for the gastric carcinogenesis.  
In conclusion, CDX2 expression was associated with IM grade 
regardless of IM subtype, and it was frequent in the dysplasia 
group. These results suggest that CDX2 expression might play 
an important role in the progression of IM which environments 
provide neoplastic change.
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